Dr. Drakoulis Yannoukakos is Director of Research in the field of Human Genetics at the Molecular Diagnostics Laboratory. He graduated from the Chemistry Department of Aristotle University of Thessaloniki in 1984. He then completed his MSc in Enzymology at Paris XI and his Doctorate in Biochemistry at Paris XII (1987-1991). He worked as a post-doctoral fellow in the Molecular Medicine Department of Beth Israel Hospital, Harvard Medical School (1991-94) and then in the Molecular Pharmacology of  New York University Medical School (1994-95). He was appointed to NCSR “Demokritos” as a Researcher C’ in 1995, while he created the Molecular Diagnostics Laboratory in 1997, which later developed as a reference laboratory in the field of Cancer Genetics in Greece. He was a Faculty member at the Greek Open University. He is a visiting Professor in the following Post-graduate Programs: Clinical Biochemistry – Molecular Diagnostics, Dept. of Biology, Athens University, Human Genetics, Medical School, University of Thessaly, School of Dentistry, University of Athens, Human Genetics, Democritus University of Thrace and Oncogenesis and Therapy, University of Crete & National Hellenic Research Foundation.  His research focuses on the analysis of Hereditary Cancer Predisposition Syndromes and Rare Diseases. He has published more than 140 articles in peer-reviewed journals and has been a reviewer in international journals and funding institutions. He has supervised fourteen completed PhD theses in the field of Cancer Genetics. He has received research funding from the General Secretariat for Research and Technology, the European Union, the Hellenic Association of Women with Breast Cancer “Alma Zois”, the Hellenic Cooperative Oncology Group, the Hellenic Society of Medical Oncology and Pharmaceutical Companies. He participates in major international consortia on Cancer Genetics (Consortium of Investigators of Modifiers of BRCA1 and BRCA2 – CIMBA, Breast Cancer Association Consortium – BCAC, Evidence-based Network for the Interpretation of Germline Mutant Alleles – ENIGMA, Ovarian Cancer Association Consortium – OCAC, The Triple Negative Breast Cancer Consortium- TNBCC, and The PALB2 Consortium).

Full list of publications: PubMed link